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The present consensus panel recommendations of the 36th
Bethesda Conference for eligibility and disqualification of
competitive athletes are predicated on the prior diagnosis of
cardiovascular abnormalities. However, the methodology by
which these diseases are identified (including preparticipa-
tion screening) and how athletes come to evaluation for
competitive eligibility, may involve several scenarios. First,
athletes may be referred for assessment of clinical symptoms
or signs. Second, fortuitous recognition may occur in
routine clinical practice, triggered by findings on history and
physical examination, such as a heart murmur. Third, young
athletes may be suspected of having cardiovascular disease
by virtue of formalized large population screening examina-
tions that are customary before participation in competitive
athletics (1).
PREPARTICIPATION SCREENING
Indeed, the ultimate objective of preparticipation screening
carried out in general populations of trained athletes is the
recognition of “silent” cardiovascular abnormalities that can
progress or cause sudden cardiac death. Such screening
efforts have the capability of raising the clinical suspicion of
several cardiovascular diseases—usually by virtue of a heart
murmur, regarded to be of potential clinical significance,
cardiac symptoms (e.g., exertional chest pain, dispropor-
tionate dyspnea, or impairment in consciousness), or a
family history of heart disease or sudden unexpected death.
However, a major obstacle to implementation of large-scale
screening in the U.S. is the substantial number of young
athletes eligible for evaluation (about 10 to 12 million) and
the rarity of the cardiac diseases capable of causing sudden
death in this population (estimated prevalence, less than or
equal to 0.3%) (2).
Customary screening strategies for U.S. high school and
college athletes is confined to history-taking and physical
examination, generally acknowledged to be limited in its
power to consistently identify important cardiovascular
abnormalities. In one retrospective study, only 3% of trained
athletes who died suddenly of heart disease (and had been
exposed to preparticipation screening) were suspected of
harboring cardiovascular disease on the basis of history and
physical examination—and none had been disqualified from
competition (3). Although most trained athletes with occult
cardiovascular disease are asymptomatic, the prior history of
exertional-related syncope in a young athlete unavoidably
raises the consideration of a number of diseases known to
cause sudden cardiac death, including hypertrophic cardio-
myopathy (HCM) and ion-channel disorders, but in par-
ticular should also heighten the level of clinical suspicion for
congenital coronary anomalies of wrong sinus origin (4).
Furthermore, the quality of cardiovascular screening for
U.S. high school and college athletes, particularly the design
of approved questionnaires, has come under scrutiny regard-
ing inadequacies (5,6) when measured against American
Heart Association (AHA) recommendations (1) (Table 1).
Legislation in several states allows health care workers with
vastly different levels of training and expertise (including
chiropractors and naturopathic clinicians) to conduct
preparticipation sports examinations, often under subopti-
mal conditions. Improvement in this screening process,
including the training level of examiners, would undoubt-
edly result in a greater number of athletes identified with
previously unsuspected but clinically relevant cardiovascular
abnormalities. Indeed, development and dissemination of a
standardized and uniform national preparticipation history
and physical examination form for medical screening in all
high schools and colleges (which incorporates the AHA
recommendations) would be the most practical approach for
achieving this goal.
Certainly, the diagnosis of genetic diseases, such as
HCM, arrhythmogenic right ventricular cardiomyopathy
(ARVC), long QT and Brugada syndromes, and other
inherited arrhythmia syndromes in asymptomatic patients
has now taken on even greater relevance. This is because
individuals judged to be at sufficiently high-risk may be
eligible for primary prevention of sudden cardiac death with
an implantable cardioverter-defibrillator (7,8).
Conversely, in Italy, for the past 25 years, a formal
national preparticipation screening and medical clearance
program has been mandated for young competitive athletes
in organized sports programs (9,10). The Italian system is
unique by virtue of requiring annual evaluations that rou-
tinely include a 12-lead electrocardiogram (ECG) as well as
a history and physical examination; the ECG itself has
proven most useful in the identification of many previously
undiagnosed athletes with HCM (10). However, such
screening efforts may be complicated by the substantial
proportion of false-positive test results that potentially
represent a major burden to athletes, their families, and the
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testing facilities. Obstacles in the U.S. to implementing
obligatory government-sponsored national screening in-
cluding ECGs or echocardiograms are the particularly large
population of athletes to screen, major cost-benefit consid-
erations, and the recognition that it is impossible to abso-
lutely eliminate the risks associated with competitive sports
(1,2). Nevertheless, some volunteer-based small-scale
screening programs using portable echocardiograms to ex-
amine high-school athletes on the field for HCM have
emerged.
Systematic preparticipation cardiovascular screening, pri-
marily to exclude atherosclerotic coronary artery disease in
older athletes, is not customary practice. Such persons are
largely participants in individual athletic activities such as
road and marathon racing, or in a variety of other organized
master’s sports (11).
DIAGNOSTIC TESTING STRATEGIES
When a cardiovascular abnormality is initially suspected (by
formal screening or otherwise), the diagnostic strategy
should focus on the systematic exclusion of those conditions
known to cause sudden death in young athletes; these
approaches include echocardiography, ECG, history, and
physical examination. Additional noninvasive (and invasive)
testing with cardiac magnetic resonance imaging (CMR),
exercise testing, ambulatory Holter ECG recording, im-
planted loop recorder, tilt table examination, or electro-
physiologic testing with programmed stimulation can be
considered in selected patients. Diagnostic myocardial bi-
opsies are used only selectively in athletes suspected clini-
cally of myocarditis.
Despite considerable assembled data regarding DNA-
based diagnosis over the past decade, identification of
genetic cardiovascular diseases such as HCM, long QT
syndrome, and other ion-channel disorders, ARVC, and
Marfan syndrome continues to be made through clinical
testing in the vast majority of cases, and this will remain so
in the foreseeable future. At present, genetic testing is not
easily available on a routine clinical basis for most genetic
heart diseases, or for application to large athletic popula-
tions given the expensive and complex methodologies in-
volved and the genetic heterogeneity characteristic of these
diseases (12).
Echocardiography. Two-dimensional echocardiography is
the principal diagnostic imaging modality for clinical iden-
tification of HCM by demonstrating otherwise unexplained
and usually asymmetric left ventricular (LV) wall thickening
(12,13). In this regard, a maximal LV end-diastolic wall
thickness of 15 mm or more (or on occasion, 13 or 14 mm)
is the absolute dimension generally accepted for the clinical
diagnosis of HCM in an adult athlete (two or more standard
deviations from the mean relative to body surface area;
z-score of two or more in children) (12,13); however, any
specific LV wall thickness (including normal) is theoretically
compatible with the presence of a mutant HCM gene
(12,14). Echocardiography would also be expected to detect
and define other specific and relevant congenital structural
abnormalities associated with sudden death or disease pro-
gression in young athletes such as valvular heart disease
(e.g., mitral valve prolapse and aortic valve stenosis), aortic
root dilatation and mitral valve prolapse in Marfan or
related syndromes, and LV dysfunction and/or enlargement
(evident in myocarditis and dilated cardiomyopathy). Such
diagnostic testing requires interpretation by physicians
trained in echocardiography, but cannot guarantee full
recognition of all relevant lesions, and some important
diseases may escape detection despite expert screening
methodology. For example, the HCM phenotype may not
be evident when echocardiography is performed in the
pre-hypertrophic phase (i.e., a patient less than 14 years
of age) (12). Annual serial echocardiography is recom-
mended in HCM family members throughout adoles-
cence (12,14).
Electrocardiography. The 12-lead ECG may be of use in
the diagnosis of cardiovascular disease in young athletes,
and has been promoted as a practical and cost-effective
strategic alternative to routine echocardiography for
population-based preparticipation screening. For example,
the ECG is abnormal in up to 75% to 95% of patients with
HCM, and often before the appearance of hypertrophy
(12). The ECG will also identify many individuals with the
long QT, Brugada, and other inherited syndromes associ-
ated with ventricular arrhythmias. It raises the suspicion of
myocarditis by premature ventricular complexes and ST-T
abnormalities, or ARVC by T-wave inversion in leads V1
through V3 and low amplitude potentials (epsilon waves)
(1,2). Of note, however, a not inconsequential proportion of
genetically affected family members with long QT syn-
drome may not express QT interval prolongation, and ECG
abnormalities are usually absent in random recordings from
patients with congenital coronary artery anomalies (4).
Other tests. In those cases in which the echocardiogram is
normal or borderline for LV hypertrophy, but a suspicion
Table 1. AHA Consensus Panel Recommendations for
Preparticipation Athletic Screening (1)
Family History
1. Premature sudden cardiac death
2. Heart disease in surviving relatives less than 50 years old
Personal History
3. Heart murmur
4. Systemic hypertension
5. Fatigue
6. Syncope/near-syncope
7. Excessive/unexplained exertional dyspnea
8. Exertional chest pain
Physical Examination
9. Heart murmur (supine/standing*)
10. Femoral arterial pulses (to exclude coarctation of aorta)
11. Stigmata of Marfan syndrome
12. Brachial blood pressure measurement (sitting)
*In particular, to identify heart murmur consistent with dynamic obstruction to left
ventricular outflow. From Maron BJ, et al. Circulation 1996;94:850–6, reprinted with
permission of the American Heart Association.
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for HCM persists (often due to an abnormal 12-lead ECG),
CMR may be useful in clarifying wall thickness or detecting
segmental areas of hypertrophy in selected regions of the LV
chamber which may be more difficult to image reliably with
conventional echocardiography, such as anterolateral free
wall or apex (15,16).
Definitive identification of congenital coronary artery
anomalies of wrong sinus origin usually requires sophisti-
cated laboratory imaging, including multi-slice computed
tomography or coronary arteriography. However, in young
athletes it is possible to raise the suspicion of these malfor-
mations with transthoracic or transesophageal echocardiog-
raphy or CMR imaging. Often, ARVC cannot be diag-
nosed reliably with echocardiography, and CMR is probably
the most useful noninvasive test for identifying the struc-
tural abnormalities in this condition (i.e., right ventricular
enlargement, wall motion abnormalities, adipose tissue re-
placement within the wall, and aneurysm formation); how-
ever, CMR is not an entirely sensitive or specific diagnostic
modality in ARVC (17).
ATHLETE’S HEART AND CARDIOVASCULAR DISEASE
Systematic training in endurance or isometric sports may
trigger physiologic adaptations and structural cardiac re-
modeling, including increased LV wall thickness, enlarged
ventricular and atrial cavity dimensions, and calculated
cardiac mass, in the presence of normal systolic and diastolic
function (i.e., athlete’s heart) (18). The magnitude of
physiologic hypertrophy may also vary according to the
particular type of sports training. Other adaptations to
training include a variety of abnormal 12-lead ECG pat-
terns in about 40% of elite athletes, which not infrequently
mimic those of cardiac disease (i.e., increased R- or S-wave
voltages, Q waves, and repolarization abnormalities) (19).
Frequent and/or complex ventricular tachyarrhythmias on
ambulatory (Holter) ECG are not uncommonly found in
athletes and can also mimic certain cardiac diseases, includ-
ing myocarditis (20).
Clinical distinctions between physiologic athlete’s heart
and pathologic conditions (18–23) have critical implications
for trained athletes, because cardiovascular abnormalities
may trigger disqualification from competitive sports to
reduce the risk of sudden death or disease progression. An
over-diagnosis may lead to unnecessary restrictions, depriv-
ing athletes of the psychological, social, or possibly (in some
elite athletes) economic benefits of sports (2).
Morphologic adaptations of athlete’s heart can closely
resemble certain cardiovascular diseases and lead to a dif-
ferential diagnosis with HCM, dilated cardiomyopathy, and
ARVC (2) (Fig. 1). Such clinical dilemmas not infrequently
arise when cardiac dimensions fall outside clinically ac-
cepted partition values. For example, 2% of highly trained
adult male athletes show relatively mild increases in LV wall
thickness (13 to 15 mm) and 15% have LV cavity enlarge-
ment greater than or equal to 60 mm (2,21,22); both fall
into a borderline and inconclusive “gray zone” for which
extreme expressions of benign athlete’s heart and mild
morphologic forms of cardiomyopathy overlap (2,22,23).
Indeed, the two most common clinical scenarios encoun-
tered that unavoidably generate ambiguous diagnoses in
trained athletes are: 1) differentiating HCM from athlete’s
heart in athletes with an LV wall thickness of 13 to 15 mm,
non-dilated and normally contractile LV, and absence of
mitral valve systolic anterior motion; and 2) differentiating
Figure 1. Gray area of overlap between athlete’s heart and cardiomyopathies, including myocarditis, hypertrophic cardiomyopathy (HCM), and
arrhythmogenic right ventricular cardiomyopathy (ARVC). ECG  electrocardiogram; LV  left ventricular. From Maron BJ, N Engl J Med
2003;349:1064–75, with permission of Massachusetts Medical Society (2).
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early presentation of dilated cardiomyopathy from athlete’s
heart with LV end-diastolic cavity dimension 60 mm or
more with low-normal LV function (i.e., ejection fraction of
50% to 55%).
Such cases with diagnostic uncertainty are not uncom-
mon and may be resolved in many athletes by a number of
independent noninvasive clinical parameters, including the
response of cardiac mass to short periods of deconditioning,
or assessment of diastolic filling (22) (Fig. 2). Clarification
of such diagnostic ambiguities may also be achieved with
CMR imaging, genotyping, and serial acquisition of clinical
and morphologic evidence over time.
doi:10.1016/j.jacc.2005.02.007
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GENERAL CONSIDERATIONS
The most common congenital heart lesions that have been
associated with sudden death during sports participation are
hypertrophic cardiomyopathy, coronary artery anomalies,
Marfan syndrome, and aortic valve disease (1–3). Less
common lesions include complex defects, such as transpo-
sition and single ventricle, and those with associated pul-
monary vascular disease.
The recommendations presented are intended to provide
broad guidelines for patients with congenital heart defects
(4). When questions about the safety of sports participation
arise, there is no substitute for a comprehensive evaluation
by a knowledgeable and experienced physician. Exercise
testing can be useful, particularly if symptoms, the electro-
cardiogram (ECG), and blood pressure are monitored
during conditions that simulate the sport in question.
Arrhythmias discussed in this Task Force are usually iden-
tified by exercise testing or some form of long-term moni-
toring (including ambulatory Holter and event recording).
Serial evaluations may be required because of changing
hemodynamic status with time.
TYPES OF CONGENITAL DEFECTS
Atrial septal defect (ASD)— untreated. Most children
with ASD are asymptomatic, and closure is usually carried
out before they are active in competitive sports. An ECG
and echocardiogram are required for evaluation. Small atrial
defects are characterized by minimal or no right ventricular
volume overload, moderate or large defects have significant
volume overload but pulmonary hypertension is unusual.
Recommendations:
1. Athletes with small defects, normal right heart vol-
ume, and no pulmonary hypertension can participate
in all sports.
2. Athletes with a large ASD and normal pulmonary
artery pressure can participate in all competitive sports.
3. Athletes with an ASD and mild pulmonary hyperten-
sion can participate in low-intensity competitive
sports (class IA). Patients with associated pulmonary
vascular obstructive disease who have cyanosis and a
large right-to-left shunt cannot participate in com-
petitive sports.
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